Lecture 4 and 5: Drugs to Treat Type II Diabetes

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/67

encourage image

There's no tags or description

Looks like no tags are added yet.

68 Terms

1
New cards

GLP-1

• Secreted from L-cells in the distal intestinal mucosa

• Rises within minutes of food ingestion

• Stimulates insulin secretion

• Suppresses glucagon secretion

• Slows gastric emptying

• Increases satiety (promotes fullness and decreases food intake)

2
New cards

GIP

• Secreted by K-cells in the intestine

• Increases insulin secretion

• No effect on glucagon, gastric motility, or satiety

3
New cards

Dipeptidyl Peptidase-4 (DPP-4)

GLP-1 and GIP are rapidly inactivated by ___________________________

4
New cards

Sodium glucose cotransporter-2 (SGLT-2)

Responsible for ~90% of filtered glucose reabsorption

5
New cards

180 mg/dL

Normal renal threshold for glucosuria occurs at plasma glucose of ___________________

6
New cards

•Medical nutrition therapy [MNT], physical activity, weight loss, smoking cessation, and psychological support

-Initial weight loss goal of 5%

-Carbohydrate counting

Lifestyle Modifications for T2DM

7
New cards

Lifestyle Modifications + Metformin

What is the first step to Overall Approach of the Management of T2DM

8
New cards

Metformin

the preferred initial pharmacologic agent for the treatment of Type 2 Diabetes

9
New cards

Metformin

• Decreases hepatic glucose production*

• Activation of AMP-activated protein kinase in hepatocytes

• Decreases intestinal glucose absorption, increased insulin sensitivity

10
New cards

Metformin

Indications:

T2DM treatment, polycystic ovarian syndrome (PCOS)

Off-label uses:

T2DM prevention, gestational DM, antipsychotic-induced weight gain

11
New cards

Biguanide

What type of drug is metformin?

12
New cards

Metformin

BBW: Drug accumulation can lead to lactic acidosis Risk is increased in moderate-to-severe renal disease or hypoperfusion (hepatic impairment, CHF, sepsis, dehydration, excessive alcohol consumption)

13
New cards

Metformin

ADVERSE EFFECTS:

-Diarrhea (transient and dose dependent)

• B12 deficiency --> macrocytic anemia

• Metallic taste

• Rare: Lactic acidosis, hepatitis

14
New cards

Metformin

-Contraindicated with Radiocontrast dye

-Discontinue on the day of procedure and resume 2-3 days later due to risk of acute kidney injury from dye

15
New cards

-A1C

-hepatic function

-renal function

-B12

What should you monitor for in a patient taking metformin?

16
New cards

Patient With ASCVD, CKD, & HF

When do you use a Combination Therapy for T2DM

17
New cards

GLP-1 Receptor Agonist or SGLT2-Inhibitor

If patient has established ASCVD or is at high risk of developing ASCVD, has established CKD, or established HF, add on a ________________________ or ______________________________

18
New cards

SGLT2-Inhibitor

If a pt with T2DM has HF or CKD that predominates, what treatment addition is preferred?

19
New cards

GLP-1 Receptor Agonists

-Synthetic GLP-1; stimulate "incretin effect" and promote insulin secretion from pancreas in response to high oral glucose levels (resistant to DPP-4 degradation)

• Suppress inappropriate glucagon secretion; slow gastric emptying, which increases satiety

20
New cards

-Exenatide

-Liraglutide

-Dulaglutide

-Lixisenatide

-Semaglutide

GLP-1 Receptor Agonists

21
New cards

GLP-1 Receptor Agonists

Indications:

-T2DM

-weight management

• Reduction of major adverse CV events (MACE) in adults with T2DM with established CV disease

22
New cards

-Liraglutide

-Semaglutide

-Dulaglutide

GLP-1 RAs that have proven CV benefit

23
New cards

Liraglutide

GLP-1 RA that can reduce CKD progression

24
New cards

GLP-1 Receptor Agonists

Contraindications

• Hypersensitivity, history of or family history of medullary thyroid carcinoma (MTC) or in patients with multiple

endocrine neoplasia syndrome type 2

(MEN2)

25
New cards

GLP-1 Receptor Agonists

ADVERSE EFFECTS:

• GI Intolerance (Nausea, bloating, constipation)

• Acute renal failure has been reported

• Weight loss

• Injection site reactions, acute pancreatitis (rare)

26
New cards

Tirzepatide

-Agonists for GLP-1 and GIP

-Once a week subcutaneous injection

-A Novel, Dual-Targeted Treatment for Type 2 Diabetes

27
New cards

Tirzepatide

ADVERSE EFFECTS:

-stomach pain

-n/v

-pancreatic and gall bladder issues

28
New cards

Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2-i)

-Inhibition of SGLT-2 in the proximal renal tubules, to block glucose reabsorption

• Enhance renal excretion of glucose

29
New cards

-Canaglifozin

-Dapaglifozin

-Empaglifozin

-Ertugliflozin

Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2-i)

30
New cards

Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2-i)

Indications:

• T2DM (ASCVD risk reduction, HF hospitalizations, CKD progression)

• HF

31
New cards

Canaglifozin

-SGLT2-i

-for T2DM, reduced MACE in adulst with T2DM and CVD

-reduced ESRD, doubling of SCr, CV death, and HHF in adults with T2DM and diabetic nephropathy with albuminuria

32
New cards

Dapagliflozin

-SGLT2-i

-for T2DM, and reduces risk of HHF in adults with T2DM and establish CVD or multiple CV risk factors

-reduced risk of CV death and HHF in adults with HFrEF

-new indication for pts with CKD with and without T2DM to reduce risk of kidney failure and CV or renal death

33
New cards

Empaglifozin

-SGLT2-i

-for T2DM and reduced risk fo CV death in adults with T2DM and established CVD

34
New cards

Ertuglifozin

-SGLT2-i

-only FDA labeled indication is for T2DM

35
New cards

Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2-i)

Contraindications

• Hemodialysis

• eGFR

36
New cards

45

SGLT2-i has a Less efficacy eGFR < _______ mL/min

37
New cards

Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2-i)

ADVERSE EFFECTS:

• Genital mycotic infections (vaginal yeast infections in females), UTIs

• Osmotic diuresis, hypotension, hypovolemia

• Weight loss

• Amputations (boxed warning)

• Bone fractures

• Euglycemic ketoacidosis risk

• ↓ TG with slight ↑ HDL and LDL

38
New cards

-A1C

-Renal Function

-Electrolytes

-BP

-Lipid Panel

what should you monitor in a pt that is taking a SGLT2-i

39
New cards

• Dipeptidyl peptidase 4 inhibitor (DPP-4i)

• GLP-1 RA

• SGLT2-i

• Thiazolidinedione (TZD)

Combination Therapy for T2DM that need to minimize hypoglycemia

40
New cards

• GLP-1 RA with good efficacy for weight loss

• SGLT2-I

Combination Therapy for T2DM that need to minimize weight gain or promote weight loss

41
New cards

• Sulfonylurea (SU)

• TZD

Combination Therapy for T2DM that need to prohibit high costs

42
New cards

Dipeptidyl Peptidase-4 Inhibitors (DPP-4i)

ADVERSE EFFECTS:

• Most common: Nasopharyngitis, upper respiratory tract infections

• Heart failure (avoid saxagliptin and alogliptin)

• Severe pancreatitis (rare)

• Joint pain (FDA-warning)

• Hypersensitivity: urticaria, angioedema, anaphylaxis, Stevens-Johnson syndrome

43
New cards

Dipeptidyl Peptidase-4 Inhibitors (DPP-4i)

-Inhibit dipeptidyl peptidase-4, the enzyme responsible for the breakdown of GLP-1 and GIP (incretin hormones), to allow for increase in circulating incretins, including GLP-1

• Decrease glucagon production

• Improve insulin response to high glucose levels

• Do not significantly alter gastric emptying, with limited effects on satiety and weight loss

44
New cards

-Sitagliptin

-Saxagliptin

-Linagliptin

-Alogliptin

Dipeptidyl Peptidase-4 Inhibitors (DPP-4i)

45
New cards

Thiazolidinediones (TZD)

-Binds to the peroxisome proliferator activator receptor-gamma (PPAR- gamma), located on fat and vascular cells, which leads to transcription of several genes involved in glucose and lipid metabolism

• Enhances insulin sensitivity at muscle, fat, and liver to directly reduce insulin resistance

46
New cards

-Pioglitazone

-Rosiglitazone

Thiazolidinediones (TZD)

47
New cards

Thiazolidinediones (TZD)

A second-line therapy to add on to metformin; consider where need to minimize hypoglycemia OR minimize costs

• Can be used as monotherapy for patients who cannot take metformin

48
New cards

Thiazolidinediones (TZD)

Contraindications

• NYHA Class III/IV heart failure (HF)

49
New cards

Thiazolidinediones (TZD)

ADVERSE EFFECTS:

• Fluid retention and edema

• Macular edema

• Weight gain (5 kg)

• BBW: HF - may exacerbate or cause HF

• Bladder cancer?

• Fractures

50
New cards

Sulfonylureas (SU)

-Bind to sulfonylurea receptor (SUR1) to close ATP-sensitive K+ channels in the β-cell membrane leading to an influx of calcium ions and exocytosis of insulin containing granules eventually ↑ pancreatic secretion of insulin

51
New cards

-Glipizide

-Glimepiride

-Glyburide

Sulfonylureas (SU)

52
New cards

Sulfonylureas (SU)

A second-line therapy to add on to metformin; consider where need for cost minimization

• Can be used as monotherapy for patients who cannot take metformin

53
New cards

Sulfonylureas (SU)

ADVERSE EFFECTS:

• Hypoglycemia: most common adverse effect

• Weight gain

• Less common: skin rash, hemolytic anemia, GI upset

54
New cards

• T1DM or DKA

• Hypersensitivity or sulfonamide allergy

contraindications for Sulfonylureas (SU)

55
New cards

Insulin

-first line therapy in T2DM if symptomatic or very high blood glucose levels

• Especially if catabolic features present (weight loss, hypertriglyceridemia, ketosis)

• To combination therapy if glycemic targets not met after 3 months of combo therapy

56
New cards

• Meglitinides

• Alpha-glucosidase inhibitors

• Bile acid resins/sequestrants

• Bromocriptine

• Pramlintide

Other FDA Approved Add-On Agents for T2DM Not Included in ADA Treatment Algorithm

57
New cards

Meglitinides/Glinides (GLNs)

-binds to site adjacent to the sulfonylurea receptor to stimulate insulin secretion from the β-cells of the pancreas in the presence of glucose

-an add on agent for T2DM

-consider with erratic meal intake

58
New cards

• Repaglinide

• Nateglinide

Meglitinides/Glinides (GLNs)

59
New cards

Meglitinides/Glinides (GLNs)

ADVERSE EFFECTS:

• Hypoglycemia (less than SUs)

• Weight gain

60
New cards

α-Glucosidase Inhibitors (AGi)

-competitively inhibits intestinal α-glucosidase enzymes that line the brush border of the small intestine (maltase, isomaltase, sucrase, glucoamylase)

• Delays the absorption and breakdown of sucrose and complex carbohydrates to monosaccharides

• Reduce rise in post prandial glucose

61
New cards

-Acarbose

-Miglitol

α-Glucosidase Inhibitors (AGi)

62
New cards

α-Glucosidase Inhibitors (AGi)

Contraindications:

• Chronic intestinal disease, inflammatory bowel disease, colonic ulceration or intestinal obstruction

63
New cards

α-Glucosidase Inhibitors (AGi)

• Must be taken 3x/day with first bite of each meal

• Decrease prandial insulin

dose if initiated together

• If hypoglycemia occurs,

glucose required

64
New cards

α-Glucosidase Inhibitors (AGi)

ADVERSE EFFECTS:

-undigested carbohydrates

leads to gas production due to their fermentation in the colon

• Flatulence, bloating, abdominal pain, diarrhea

65
New cards

Pramlintide

-Amylin analog

• Decrease glucagon secretion (decrease blood glucose)

• Promote satiety by delaying gastric emptying

-Adjunctive therapy added to prandial insulin

66
New cards

Pramlintide

ADVERSE EFFECTS:

-Hypoglycemia, nausea/vomiting, weight loss, headache

• Reduce prandial insulin dose by 30-50% when starting therapy

67
New cards

Pramlintide

Contraindications

• Confirmed gastroparesis

• Unable to detect hypoglycemia

68
New cards

Insulin

preferred agent for management in both T1DM and T2DM